Related Experiment Video
Updated: Mar 21, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials
Tom Wei-Wu Chen1,2,3
1Department of Oncology and Center of Excellence for Sarcoma, National Taiwan University Hospital, Taipei, Taiwan.
Summary
Eribulin showed promise in epithelioid hemangioendothelioma (EHE) but requires further study in angiosarcoma. Histology-specific approaches are crucial for developing drugs for rare sarcomas.
Area of Science:
- Oncology
- Medical Research
Background:
- Angiosarcoma and epithelioid hemangioendothelioma (EHE) are rare vascular tumors.
- Limited treatment options exist for advanced cases of these sarcomas.
Purpose of the Study:
- To evaluate the efficacy of eribulin in patients with angiosarcoma and EHE.
- To explore histology-specific responses to eribulin treatment.
Main Methods:
- Two prospective international clinical trials were conducted.
- Patients with angiosarcoma and EHE received eribulin treatment.
Main Results:
- Encouraging activity of eribulin was observed in epithelioid hemangioendothelioma.
- The role of eribulin in angiosarcoma may require further subgroup analysis for optimal patient selection.
Conclusions:
- Eribulin demonstrates potential in treating EHE.
- Histology-specific interpretation and tailored drug development strategies are vital for rare sarcoma subtypes like angiosarcoma.
